Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of dolutegravir in HIV-1-infected adults with virologic failure on a prior integrase inhibitor regimen
2009-017951-87Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir in Human immunodeficiency virus infection type 1, sponsored by ViiV Healthcare. Primary endpoint: Mean change from baseline in plasma HIV-1 RNA at Day 8. Started Apr 2011; status: completed.
02
Drugs
dolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-017951-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017951-87.